WisdomAI Launches Federated Agentic Platform
Startup WisdomAI has launched its Federated Agentic Intelligence Platform, designed to automate decisions across fragmented data silos without moving the data itself. The platform aims to turn raw enterprise data into trusted actions, a key challenge in deploying AI at scale.
WisdomAI's platform is spearheaded by co-founder and CEO Soham Mazumdar, who previously co-founded Rubrik and held engineering leadership roles at Facebook and Google, where he contributed to the core search infrastructure. The company has secured $73 million in total funding from prominent investors, including a recent $50 million Series A round led by Kleiner Perkins with participation from NVIDIA's venture arm, NVentures. The platform's architecture is built to avoid the "warehouse wait" by not moving or duplicating data. It uses a "Zero-ETL" approach, connecting directly to existing data sources like SaaS applications, cloud warehouses, and operational databases in real-time. This is designed to eliminate the need for costly and time-consuming data pipelines. A core technical component is the analytics-native Model Context Protocol (MCP) client, which allows AI agents to reason across these distributed systems. Complementing this is the Adaptive Context Engine (ACE), which learns and codifies an organization's undocumented "tribal knowledge" to reconcile conflicting metrics and provide a shared context for the AI agents. For students aspiring to work on such systems, WisdomAI's hiring for software engineers highlights a demand for skills in Python, Kubernetes, Terraform, Node.js, React, and TypeScript. Experience in building scalable cloud infrastructure and working with ML and data pipelines are also key qualifications. In the fintech sector, the underlying principle of federated learning is already being used to improve fraud detection models across multiple banks without sharing sensitive customer data. This approach allows for collaborative model training while maintaining data privacy and complying with regulations like GDPR. Within biotech and pharmaceuticals, agentic AI is being applied to accelerate drug discovery and streamline clinical trials. These AI agents can autonomously analyze vast amounts of research data, screen molecules, and optimize patient recruitment for clinical studies, significantly reducing development timelines.
